Cue Biopharma, Inc.
CUE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645460
In the last 90 days, Cue Biopharma, Inc. insiders filed 0 open-market purchases and 5 sales; 50 institutions reported holding it in 13F filings for Q2 2026, worth $52.2M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 12, 2026
- $127.1M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $824.3K in total
- 5
- 13F holdersQ2 2026, −7 vs. previous quarter
- 50
- 13F valueReported value at the end of Q2 2026
- $52.2M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $27.5M
- +195.7% year over year
- Net income, FY2025
- -$26.6M
- No comparable prior period
- Free cash flow, FY2025
- -$21.9M
- No comparable prior period
- Revenue, Q2 FY2026
- $7.88M
- +166.7% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $26.6M (96.9% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 862.8K
- Shares sold short
- Change
- +70.2K
- +8.9% vs. previous
- Days to cover
- 7.57
- At average daily volume
Superinvestors holding CUE, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding CUE at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Cue Biopharma, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 14, 2026 (view filing)9:39 PM ET | Oct 12 | 2 days | Ray SumitaChief Legal Compliance Officer | SSale | −1.84K | $28.05 | −$51.7K | −1.6%116.7K after | |
| Oct 14, 2026 (view filing)9:38 PM ET | Oct 12 | 2 days | Meluzio Michael VincentVP, Prin. Accounting Officer | SSale | −1.14K | $28.05 | −$32.1K | −2.3%47.8K after | |
| Oct 14, 2026 (view filing)9:37 PM ET | Oct 12 | 2 days | Lin Shao-LeeChief Executive Officer | SSale | −11.1K | $27.55 | −$305.5K | −1.6%694.9K after | 2 lots |
| Aug 17, 2026 (view filing)6:22 PM ET | Aug 13 | 4 days | Ray SumitaChief Legal Compliance Officer | SSale | −8.83K | $30.09 | −$265.6K | −6.9%118.5K after | 3 lots |
| Aug 17, 2026 (view filing)6:19 PM ET | Aug 13 | 4 days | Meluzio Michael VincentVP, Prin. Accounting Officer | SSale | −5.63K | $30.09 | −$169.3K | −10.3%49.0K after | 3 lots |
| Aug 14, 2026 (view filing)8:46 PM ET | Aug 12-13 | 2 days | Lin Shao-LeeChief Executive Officer | SSale | −58.3K | $27.58 | −$1.61M | −7.6%706.0K after | 5 lots |
| Jan 2, 2026 (view filing)4:00 PM ET | Dec 30, 2025 | 3 days | Sarraf PashaDirector | PPurchase | +323.9K | $0.308 | +$99.7K | New position323.9K after | 5 lots |
| Dec 18, 2024 (view filing) | Dec 16 | 2 days | Passeri Daniel RCHIEF EXECUTIVE OFFICER | PPurchase | +30.0K | $1.03 | +$30.9K | +22.3%164.6K after | |
| Aug 29, 2023 (view filing) | Aug 25 | 4 days | Suri AnishPRESIDENT AND CSO | PPurchase | +4.00K | $2.76 | +$11.0K | +3.0%135.6K after | |
| Aug 16, 2023 (view filing) | Aug 14 | 2 days | Passeri Daniel RCHIEF EXECUTIVE OFFICER | PPurchase | +3.00K | $2.86 | +$8.58K | +2.3%134.6K after |
Top 10 13F holders, Q2 2026
See all 50 holdersThe largest institutional positions in Cue Biopharma, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bleichroeder LP | 370,682 | $11.7M | 2.09% | −6,448,482−94.6% | Reduced |
| Driehaus Capital Management LLC | 292,144 | $9.22M | 0.05% | +292,144 | New |
| Vanguard Capital Management LLC | 161,700 | $5.10M | 0.00% | −2,295,752−93.4% | Reduced |
| Ikarian Capital, LLC | 104,364 | $3.29M | 0.54% | +104,364 | New |
| Polygon Management Ltd. | 93,819 | $2.96M | 0.48% | +93,819 | New |
| StemPoint Capital LP | 66,995 | $2.11M | 0.37% | +66,995 | New |
| BlackRock, Inc. | 57,807 | $1.82M | 0.00% | −391,354−87.1% | Reduced |
| ADAR1 Capital Management, LLC | 55,193 | $1.74M | 0.08% | +55,193 | New |
| Lion Point Capital, LP | 52,928 | $1.67M | 7.99% | −2,149,926−97.6% | Reduced |
| Squadron Capital Management LLC | 50,000 | $1.58M | 0.54% | +50,000 | New |
Holders of 5% or more of CUE
See all 4 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Cue Biopharma, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Bleichroeder LP | 13G/A | 8.77%663.0K shares | −1.22 ppfrom 9.99% | Mar 11, 20244 filings | Nov 10, 2026 | SEC |
| Strome Mark E | 13G/A | 8.50%644.9K shares | – | Oct 8, 20261 filing | Oct 8, 2026 | SEC |
| Driehaus Capital Management LLC | 13G | 6.96%292.1K shares | New | Aug 14, 20261 filing | Aug 14, 2026 | SEC |
| Lin Shao-Lee | 13D | 6.20%467.2K shares | New | Aug 21, 20261 filing | Aug 21, 2026 | SEC |